Mark your calendars: The 67th Annual Meeting & Exposition of the American Society of Hematology (ASH) is less than two weeks away! The highly anticipated annual meeting will be held from 6–9th December 2025 in Orlando, Florida, with a fully integrated virtual platform. As the premier scientific and educational gathering in haematology, ASH 2025 brings together key opinion leaders, clinicians, nurses, trainees and industry partners from across the world to showcase the frontiers of blood science, clinical care and innovation.
touchHAEMATOLOGY will be bringing you the highlights, so keep an eye out on our social media and website for the latest news!
Click here to view the coverage from ASH 2024
What to expect
- Six late-breaking abstracts have been selected, preview them here!
- Virtual Platform: Opens 3rd December; allows live viewing, Q&A, and long-term access to recorded content.
- For early-career professionals and trainees, there are dedicated spaces such as the Trainee Lounge, poster sessions and ‘Meet the Scientist’ forums
- Stay informed: Watch for updates via the ASH News Daily, social media (#ASH25), and the meeting app.
The numbers
- 30,000+ attendees
- 5,000+ novel abstracts
- 275+ exhibitors corporate supporters, academic leaders and patient-advocacy groups
Key themes to watch
- Cellular & gene therapies: Updates in CAR T-cell evolution, allogeneic platforms, gene-editing approaches and long-term outcomes from pivotal cell therapy trials
- AML & MDS innovation: Menin inhibitors, targeted agents (FLT3, IDH, KIT), emerging triplet regimens and novel hypomethylating and immune-modulating combinations
- Lymphoma: Anticipated data include bispecific antibody combinations, next-generation ADCs, CAR-T sequencing strategies and real-world evidence on newly approved therapies
- Multiple myeloma: Early-phase immunotherapies (e.g., GPRC5D/FcRH5 targets), CELMoDs, updated CAR-T durability findings and strategies for high-risk patient subsets
- General haematology: Key areas include gene therapy outcomes in sickle cell disease, novel coagulation and thrombosis management strategies and advances in hemolytic and iron-related disorders
- Transplantation progress: Graft engineering, optimized conditioning, GVHD prevention and evidence for targeted post-transplant maintenance
- Health equity & global haematology: Improving access to advanced therapies, addressing real-world disparities and implementing scalable hematology care models worldwide
For more information, visit the official ASH website.
Cite: Countdown to ASH25! touchHAEMATOLOGY. November 25th, 2025
Related content
- #ASH24: Must-know updates in multiple myeloma
- Key highlights from ASH 2024: Promising new therapies for relapsed/refractory acute myeloid leukaemia
- DREPAGREFFE: Comparing stem cell transplantation and standard-of-care in paediatric sickle cell anaemia
SIGN UP to touchHAEMATOLOGY!
Join our global community today for access to thousands of peer-reviewed articles, expert insights, and learn-on-the-go education across 150+ specialties, plus concise email updates and newsletters so you never miss out.
